Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

INTRODUCTION: Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain unex...

Descripción completa

Detalles Bibliográficos
Autores principales: Claas, Allison M., Atta, Lyla, Gordonov, Simon, Meyer, Aaron S., Lauffenburger, Douglas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244947/
https://www.ncbi.nlm.nih.gov/pubmed/30524510
http://dx.doi.org/10.1007/s12195-018-0542-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244947/
https://www.ncbi.nlm.nih.gov/pubmed/30524510
http://dx.doi.org/10.1007/s12195-018-0542-y

Ejemplares similares